ObsEva S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OBSV research report →
Companywww.obseva.com
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization.
- CEO
- William Michael Brown
- IPO
- 2018
- Employees
- 48
- HQ
- Geneva, CH
Price Chart
Valuation
- Market Cap
- $11.00M
- P/E
- -0.31
- P/S
- 0.56
- P/B
- 1.11
- EV/EBITDA
- -0.28
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -79.83%
- Net Margin
- -152.16%
- ROE
- -146.39%
- ROIC
- -126.58%
Growth & Income
- Revenue
- $19.64M · 0.00%
- Net Income
- $-29,879,000 · 48.82%
- EPS
- $-0.32 · 58.97%
- Op Income
- $-15,677,000
- FCF YoY
- 67.09%
Performance & Tape
- 52W High
- $2.14
- 52W Low
- $0.07
- 50D MA
- $0.14
- 200D MA
- $0.27
- Beta
- 0.67
- Avg Volume
- 7.95M
Get TickerSpark's AI analysis on OBSV
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 6, 23 | Loumaye Ernest | buy | 4,000,000 |
| Feb 28, 23 | Loumaye Ernest | buy | 4,000,000 |
| Feb 23, 23 | Brown William Michael | other | 250,000 |
| Jan 1, 23 | Loumaye Ernest | other | 0 |
| Jan 1, 23 | Mathers Edward T | other | 32,000 |
| Jan 1, 23 | Edfjall Catarina | other | 32,000 |
| Jan 1, 23 | VANLENT ANNE | other | 32,000 |
| Jan 1, 23 | Clancy Annette | other | 32,000 |
| Jan 1, 23 | Clancy Annette | other | 0 |
| Jan 1, 23 | O'CALLAGHAN BRIAN | other | 715,000 |
Our OBSV Coverage
We haven't published any research on OBSV yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OBSV Report →